Relationship between Parathyroid Hormone Levels and Hazards of Fracture, Vascular Events and Death in Stage 3 and 4 Chronic Kidney Disease

Authors:

Sinong Geng, MS, Graduate Student, Department of Computer Science, Princeton University, sgeng@cs.princeton.edu

Zhaobin Kuang, Ph.D., Postdoctoral Researcher, Computer Science Department, Stanford University, kuangz@stanford.edu, ORCID: 0000-0001-9295-4669

Peggy L. Peissig, Ph.D., MBA, Research Scientist & Director, Marshfield Clinic Research Institute, Center for Computational and Biomedical Informatics, peissig.peggy@marshfieldclinic.org ORCID: 0000-0003-4156-0189

David Page, PhD, Professor, University of Wisconsin-Madison, Department of Biostatistics and Medical Informatics, Department of Computer Sciences, page@biostat.wisc.edu, ORCID: 0000-0003-0576-2912

Laura Maursetter, DO, Assistant Professor of Medicine, University of Wisconsin School of Medicine & Public Health, Department of Medicine, lmaursetter@medicine.wisc.edu

Karen E. Hansen, MD, MS*, Associate Professor of Medicine, University of Wisconsin School of Medicine & Public Health, Department of Medicine, keh@medicine.wisc.edu, ORCID: 000-0003-4338-6073

*Corresponding author:

Hansen KE, Department of Medicine, University of Wisconsin School of Medicine & Public Health, Mailbox 4124 Medical Foundation Centennial Building, 1685 Highland Avenue, Madison, WI, 53705-2281, USA. Telephone: 608-263-3457, FAX: 608-263-7353, Email: keh@medicine.wisc.edu

Running title: PTH and Fractures, Vascular Events and Death

Abstract word count: 295

Manuscript word count: 2475 of 3500 max

Abstract (300 words, limit =300)

Background and Objectives: Chronic kidney disease (CKD) affects ~20% of older adults and secondary hyperparathyroidism (HPT) is a common condition in these patients. Studies have linked HPT to a greater risk of fractures, vascular events and mortality. However, the optimal parathyroid hormone (PTH) level needed to minimize these events remains uncertain.

Design, setting, participants and measurements: We assessed relationships between baseline serum PTH levels and the subsequent 10-year probability of clinical fractures, vascular events and death in stage 3 and 4 CKD patients. We used Marshfield Clinic Health System electronic health records to analyze data from adult CKD patients spanning from 1985 to 2013. We required ≥ 2 PTH measurements at baseline and used ICD-9 codes to identify medical conditions, fractures, vascular events and death. In multivariate models, we assessed relationships between serum PTH and the three clinical outcomes, controlling for age, gender, co-morbidities and osteoporosis medication.

Results: 7594 subjects had a mean age of 68 ± 13 years and 55% were women. Fractures, vascular events and death occurred in 19%, 60% and 29% of the cohort, respectively. In multivariate models including the whole cohort regardless of PTH assay, the probability of fracture, vascular events and death were minimized at a PTH of 23, 50 and 50 pg/mL. Below these cutpoints, the probability of fractures and death dramatically increased. When confining the analysis to patients measured using a 2nd generation PTH assay (n=5108), the hazards of fracture, vascular events and death were minimized at a PTH of zero, 60 and 58 pg/mL. Any of these clinical outcomes was minimized at a baseline PTH of 58 pg/mL.

Conclusions: Our study suggests that parathyroid hormone levels around 60 pg/mL might reduce the risk of fractures, vascular events and death in CKD patients. Additional epidemiologic studies and randomized clinical trials are needed to confirm these findings.

Keywords: chronic kidney disease, secondary hyperparathyroidism, fractures, vascular events, mortality

Introduction

CKD affects one in five older adults (1) and 14% of the general population (2). CKD causes more deaths per year than breast or prostate cancer (2). Patients >65 years old with CKD have a higher prevalence of cardiovascular disease (70% vs. 35%) compared to individuals of the same age without CKD (2). Medicare spends almost one-fifth of its budget on CKD patient care, due to excess vascular events, fractures, infections and subsequent premature death (3) compared to patients without CKD. Secondary hyperparathyroidism (HPT) affects nearly all stage 5 (dialysis) CKD patients and over half of stage 3-4 CKD patients (4-6). The pathogenesis of hyperparathyroidism is well established (7). Declining renal 1,25(OH)₂D synthesis leads to reduced intestinal calcium absorption and lower ionized serum calcium levels. To maintain normocalcemia, the parathyroid glands released parathyroid hormone (PTH), which upregulates renal 1,25(OH)₂D synthesis to increase calcium absorption, and stimulates osteoclastic bone resorption to liberate skeletal calcium into the bloodstream.

Most cross-sectional studies in CKD patients have found an inverse relationship between PTH and bone mineral density (BMD) (5, 8-11), suggesting that HPT contributes to fractures. Researchers have also found that high PTH was associated with vascular calcification (12) and vascular events (13) in CKD patients. From these studies, we hypothesized that treating HPT in stage 3-4 CKD patients might increase BMD and reduce the risk of fractures, vascular events and death. We found weak evidence suggested that treating HPT improved bone mineral density (2 trials, 62 subjects) (14, 15) and no clinical trials demonstrating that treatment of HPT reduced vascular events or death in stage 3-4 CKD patients.

Based on expert opinion and observational studies, the National Kidney Foundation published guidelines on how to manage HPT. The 2003 guidelines (16) suggested specific PTH targets to achieve, depending on the stage of kidney disease (**Appendix Table 1**). However, the 2009 National Kidney Foundation guidelines (7) acknowledged that target PTH levels were based on expert opinion, rather than randomized clinical trials. Because vitamin D analogs can raise serum calcium and phosphorus and potentially promote vascular calcification, the 2017 National Kidney Foundation guidelines (17) reserved

treatment for patients with severe and progressive hyperparathyroidism; specific PTH targets were not recommended.

In summary, observational studies have linked HPT to lower BMD, excess fractures and excess vascular events that together would shorten lifespan. However, potential harm from use of vitamin D analogs, and lack of clinical trials proving the benefits of such therapy, have led to uncertainty about whether to treat HPT. We utilized the Marshfield Clinic Health System (MCHS) data repository to evaluate relationships between serum parathyroid hormone levels and clinical fractures, vascular events, and mortality in patients with stage 3 and 4 chronic kidney disease. Our objective was to identify the PTH level that minimized these three adverse clinical outcomes. We hypothesized that higher parathyroid hormone levels would be associated with greater probability of fractures, vascular events and death, compared to lower parathyroid hormone levels.

Materials and Methods

We utilized electronic health records of patients within the MCHS data repository from a collection period spanning ~30 years (1985 to 2013). The database includes patients' demographic characteristics, medical conditions, laboratory results, fractures, imaging results and medication use. We included patients who were 1) ≥ 21 years old, 2) had a mean GFR < 60 mL/minute during the baseline year based on the average of at least 2 measures, 3) had at least two parathyroid hormone levels measured during the baseline year during outpatient clinic visits, and 4) subsequently received medical care at Marshfield Clinic for at least 2 years, prior to November 2013. We excluded patients on dialysis and patients with primary hyperparathyroidism. We further excluded patients who had undergone parathyroidectomy, a procedure which is largely restricted to dialysis patients and is associated with increased mortality (18).

At least two ICD-9 coded clinic encounters within a 24-month interval were required to denote the presence of diabetes, hypertension or hyperlipidemia, as described elsewhere (19, 20). We used ICD-9 codes designating specific skeletal fracture sites known to reflect osteoporotic fracture including hip (ICD-9 820-822), wrist (ICD-9 813), humerus (ICD-9 812) and vertebral (ICD-9 805) fractures. We also

used ICD-9 codes to denote vascular events. We required that at least two clinical encounters noted the ICD-9 code prior to counting the vascular event, since “ruling out” such an event was often used to support the need for imaging (e.g. head CT scan to rule out stroke).

Statistical Analysis

We analyzed predictors of three clinical outcomes (fracture, vascular events, death) occurring after parathyroid hormone measurement, using the mean of two or more baseline PTH values. First, we used survival tree models (21) to identify the PTH level at which the probability of each clinical outcome was minimized. In the full survival tree model, we used all covariates while in the second or reduced model we employed the mean PTH level alone. After ten-fold cross validation, we identified the PTH level at which the probability of each outcome was minimized, then we divided patients into groups according to whether their PTH level was above or below that level. We used Cox proportional hazard ratios and Kaplan-Meier survival curves to evaluate the risks of each clinical outcome in patients with PTH below and above the “optimal” level identified by survival tree models. Our multivariate models controlled for age, gender, tobacco use, diabetes, hypertension, hyperlipidemia, vascular disease, obesity, GFR, bisphosphonate and other bone active medications (22-24).

As in other medical centers, the PTH assay used at the Marshfield Clinic Laboratory changed several times over the span of 30 years. First generation PTH assays measured PTH fragments that accumulated in renal failure but were devoid of biologic activity (25). Third generation PTH assays did not detect PTH7-84 fragments (25). Currently, the 2nd generation assay is used in the vast majority of medical centers (26). To make our study results most relevant to current clinical practice, we performed a sensitivity analysis in which the three clinical outcomes were analyzed by excluding subjects whose PTH was measured using a 1st or 3rd generation PTH assay. We performed a further sub-analysis to assess whether the optimal PTH level differed between patients with stage 3 and stage 4 CKD. We used version 3.2.3 of “R” (The R Project for Statistical Computing, <http://www.r-project.org>) for all statistical analyses.

Results

We identified 7594 eligible subjects (55% female) with a mean $\pm$ standard deviation age of 68 ± 13 years (**Table 1**). Patients received care at MCHS for 24 ± 15 years. Among the cohort, 19% sustained clinical fractures, 60% experienced vascular events and 29% died. We did not include race, body mass index, denosumab or teriparatide as co-variables due to lack of records regarding these data (race, body mass index) or too few individuals with the characteristic (use of denosumab or teriparatide). The 2010 United States Census estimated that ~19,000 people lived in Marshfield, Wisconsin and the vast majority (~95%) were Caucasian, suggesting that our cohort was largely Caucasian (27). We had no missing data for age, gender, diabetes, hypertension, hyperlipidemia, coronary artery disease, peripheral vascular disease, bisphosphonate, estrogen or testosterone therapy.

Analysis of all subjects regardless of PTH assay

Age, gender, vascular disease, obesity, GFR and PTH were significant co-variables in the multiple variable model predicting fracture (**Table 2**). The PTH value at which the probability of fracture was minimized equaled 23 pg/mL (**Figure 1**). Below this level, the 10-year probability of fracture dramatically increased. Surprisingly, at PTH values >23 pg/ml, the probability of fracture increased only modestly. In the multiple variable model predicting vascular events, age, gender, diabetes, hypertension, hyperlipidemia, obesity, GFR and PTH were significant co-variables (**Figure 1, Table 2**). The PTH value at which the probability of vascular events was minimized equaled 50 pg/mL (**Table 2, Figure 1**). Finally, age, gender, tobacco, vascular disease, diabetes, hypertension, hyperlipidemia, obesity, GFR and PTH were each significant co-variables in the multiple variable models predicting death (**Table 2**). The PTH level associated with highest probability of survival was 50 pg/mL. Just as with fractures, the probability of death increased sharply with lower PTH levels (**Figure 1**).

In a 5-year survival analysis, we applied a logistic regression to the data that included patients who were alive or deceased 5 years after the diagnosis of stage 3-4 CKD. With a 10-fold cross validation, we drew the receiver operating characteristic (ROC) curve for prediction that had an area under the curve

(AUC) value of 0.784. We used age, gender, tobacco use, vascular disease, diabetes, hypertension, hyperlipidemia, obesity, GFR, PTH, bisphosphonates, and other drugs (estrogen, raloxifene, testosterone) as covariates predicting death.

Analysis restricted to subjects measured using second generation PTH assay

Among 5108 individuals who had baseline PTH levels measured using a second generation assay, age, gender, vascular disease, osteoporosis therapy and PTH were significant co-variables in the multiple variable model predicting fracture (**Table 3**). Subsequent models suggested that a PTH level of 101 pg/mL was associated with lowest subsequent risk of fracture. However, a comparison of patients with PTH values below and above this level indicated no significant difference in the risk of fracture (**Figure 2**). In fact, Figure 2 demonstrates that a PTH level of zero was associated with the lowest probability of subsequent fracture.

In the multiple variable model predicting vascular events, age, gender, diabetes, obesity, GFR and PTH were significant co-variables (**Table 3**). In this sensitivity analysis, the probability of vascular events was lowest at a baseline PTH of 69 pg/mL (**Figure 3**). In multiple variable models predicting death, age, gender, vascular disease, diabetes, hypertension, hyperlipidemia, obesity, GFR and PTH were significant co-variables (**Table 3**). The probability of death was minimized when baseline PTH was 58 pg/mL (**Figure 3**). The composite outcome of fracture, vascular event or death was lowest at a baseline PTH of 58 pg/mL (**Figure 4**).

Probability of Fracture, Vascular Events and Death by stage of CKD

We analyzed the subgroup of 5108 patients to determine whether the optimal PTH cut point differed, based on stage of CKD. In this analysis, we grouped patients into those with an average GFR ≥ 30 mL/minute (n=3923) and a GFR < 30 mL/minute (n=1185) during the baseline year. In these analyses, we found no optimal PTH level that reduced the risk of fracture. In subjects with a GFR ≥ 30 mL/minute, a PTH of 69 pg/mL was associated with the lowest risk of vascular events. In subjects with a GFR < 30 mL/minute, a PTH of 58 pg/mL was associated with lowest risk of death. In the other subgroups, we found no clear cutpoint between PTH and clinical outcomes.

Discussion

For many years, the National Kidney Foundation recommended treating HPT in CKD patients to achieve specific PTH values (7, 16). The recommendations were based on observational studies linking high PTH to lower BMD and greater risk of vascular events. The Food and Drug Administration approved calcitriol, paricalcitol and doxercalciferol to treat HPT, based on short-term clinical trials demonstrating the ability of these vitamin D compounds to lower PTH values. Thus, clinicians had both guidelines for, and FDA-approved medications to treat, HPT. However in 2017, the National Kidney Foundation recommended against routinely treating HPT (17) due to lack of randomized, placebo-controlled clinical trials proving that such treatment improved patients' health. We found weak evidence suggested that treating HPT improved bone mineral density (2 trials, 62 subjects) (14, 15) and no clinical trials demonstrating that treatment of HTP reduced vascular events or death. We conducted the current study, in order to evaluate the association between baseline PTH levels and long-term risk of fractures, vascular events and death in a large cohort of patients medically homed at MCHS.

Our main finding was that in patients whose PTH was measured using a 2nd generation assay, fracture risk was lowest at a PTH level of zero, and fracture risk steadily rose in concert with a rising PTH. By contrast, the risk of vascular events and death were lowest when baseline PTH levels were 69 and 58 pg/mL, respectively. The composite endpoint of any adverse event was lowest when PTH equaled 58 pg/mL. In a sensitivity analysis of patients with stage 3 CKD, a PTH of 69 pg/mL was associated with the lowest subsequent risk of vascular events. Likewise in subjects with stage 4 CKD, a PTH of 58 pg/mL was associated with lowest risk of death.

PTH has been criticized as a biomarker in CKD for several reasons. First, biologically inert fragments such as PTH (7-84) accumulate as renal function declines, leading to spurious elevation of the measured PTH. Second, although most laboratories measure PTH using a 2nd generation assays, many such assays are commercially available and each has its "normal" reference range. International standardization is needed, whereby known PTH (1-84) concentrations are measured to confirm consistent

results across assays and laboratories. Third, PTH is released in response to ionized serum calcium levels, and thus has diurnal variation influenced by calcium ingestion and intestinal absorption. Reduced PTH variability would be accomplished by measuring PTH in the fasting state. Fourth, magnesium deficiency causes relative hypoparathyroidism and can be challenging to diagnose, as serum magnesium is an insensitive measure of magnesium stores. Finally, biotin supplements can falsely lower PTH values (28) and should be discontinued prior to measuring PTH.

Although PTH may not be an optimal biomarker as discussed above, we found that PTH remained a statistically significant co-variate in the multiple variable models predicting fracture, vascular events and death. The continued use of PTH as a biomarker is supported by our findings. However, several approaches are needed to improve PTH measurement including measurement of PTH in the fasting state, consistent reporting across different commercial assays, and reduced measurement of biologically inert fragments.

We acknowledge that our study has both strengths and limitations. We analyzed a large number of subjects' electronic health records. We controlled for covariates known to increase the risk of clinical outcomes. However, the nature of this epidemiologic study can only suggest, not prove, a causal relationship between PTH values and clinical outcomes. Additionally, we could not determine whether low PTH values resulted from excess calcium intake, vitamin D therapy or other factors. We had no information on why PTH was measured in subjects, or whether results prompted a specific intervention. Based on census data, our study contained very few non-Caucasian subjects. Finally, we cannot determine whether fractures were due to skeletal fragility, as the circumstances leading fractures were not available via electronic health record search terms.

In conclusion, one in five older adults has CKD and most of these patients develop secondary hyperparathyroidism. While HPT has been linked to lower BMD and greater risk of vascular events, there is no direct evidence from randomized, placebo-controlled trials to confirm that its treatment reduces fractures, vascular events or death. We undertook this study to better understand the relationship between PTH and subsequent risk of fractures, vascular events and death. Our hope was to identify a potential

PTH target that would minimize these adverse outcomes, thus guiding the design of randomized controlled clinical trials. Given the limitations of our study, it is important to verify these findings in another database. If we can confirm a proposed target PTH level at which fractures, vascular events and death are reduced, then randomized clinical trials will be needed to verify that treatment of HPT improves the health of CKD patients.

Disclosures: none

Author contributions:

SG, ZK, DP, DP and PP collected and analyzed the data.

SG created the figures.

KEH designed the study, reviewed analysis of data, drafted and revised the paper.

All authors approved the final version of the manuscript.

Acknowledgements:

Authors received no financial support for the study. We thank Bryan Robeson, Technical Manager at Marshfield Clinic Laboratory for supplying information on the PTH assays used at Marshfield Clinic.

Authors' disclosures: None

References:

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. *Jama*, 298: 2038-2047, 2007
2. Diseases NIDDK: Kidney disease statistics for the United States. 2016
3. Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, Chen JT, Cope E, Gipson D, He K, Herman W, Heung M, Hirth RA, Jacobsen SS, Kalantar-Zadeh K, Kovesdy CP, Leichtman AB, Lu Y, Molnar MZ, Morgenstern H, Nallamothu B, O'Hare AM, Pisoni R, Plattner B, Port FK, Rao P, Rhee CM, Schaubel DE, Selewski DT, Shahinian V, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, Eggers PW, Agodoa LY, Abbott KC: US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. *Am J Kidney Dis*, 66: Svi, S1-305, 2015
4. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. *Kidney Int*, 71: 31-38, 2007
5. Stavroulopoulos A, Porter CJ, Roe SD, Hosking DJ, Cassidy MJ: Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. *Nephrology (Carlton)*, 13: 63-67, 2008
6. Ramos AM, Albalade M, Vazquez S, Caramelo C, Egido J, Ortiz A: Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. *Kidney Int Suppl*: S88-93, 2008

7. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl*: S1-130, 2009
8. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K: Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. *Kidney Int*, 56: 1084-1093, 1999
9. Bianchi ML, Colantonio G, Montesano A, Trevisan C, Ortolani S, Rossi R, Buccianti G: Bone mass status in different degrees of chronic renal failure. *Bone*, 13: 225-228, 1992
10. Tsuchida T, Ishimura E, Miki T, Matsumoto N, Naka H, Jono S, Inaba M, Nishizawa Y: The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure. *Osteoporos Int*, 16: 172-179, 2005
11. Obatake N, Ishimura E, Tsuchida T, Hirowatari K, Naka H, Imanishi Y, Miki T, Inaba M, Nishizawa Y: Annual change in bone mineral density in predialysis patients with chronic renal failure: significance of a decrease in serum 1,25-dihydroxy-vitamin D. *J Bone Miner Metab*, 25: 74-79, 2007
12. Naranda J, Ekart R, Pecovnik-Balon B: Total parathyroidectomy with forearm autotransplantation as the treatment of choice for secondary hyperparathyroidism. *J Int Med Res*, 39: 978-987, 2011
13. Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A: Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease. *Int Urol Nephrol*, 44: 541-547, 2012
14. Przedlacki J, Manelius J, Huttunen K: Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. *Nephron*, 69: 433-437, 1995
15. Rix M, Eskildsen P, Olgaard K: Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. *Nephrol Dial Transplant*, 19: 870-876, 2004
16. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis*, 42: S1-201, 2003
17. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl*, 7: 1-59, 2017
18. Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, Block GA, Collins AJ: Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. *Clin J Am Soc Nephrol*, 10: 90-97, 2015
19. Magnan EM, Palta M, Johnson HM, Bartels CM, Schumacher JR, Smith MA: The impact of a patient's concordant and discordant chronic conditions on diabetes care quality measures. *J Diabetes Complications*, 29: 288-294, 2015
20. Johnson HM, Bartels CM, Thorpe CT, Schumacher JR, Pandhi N, Smith MA: Differential Diagnosis and Treatment Rates Between Systolic and Diastolic Hypertension in Young Adults: A Multidisciplinary Observational Study. *J Clin Hypertens (Greenwich)*, 17: 885-894, 2015
21. Therneau TM, Grambsch PM: *Modeling Survival Data: Extending the Cox Model*, New York, Springer-Verlag, 2000
22. Iki M, Fujita Y, Tamaki J, Kouda K, Yura A, Sato Y, Moon JS, Harano A, Hazaki K, Kajita E, Hamada M, Arai K, Tomioka K, Okamoto N, Kurumatani N: Incident fracture associated with increased risk of mortality even after adjusting for frailty status in elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Cohort Study. *Osteoporos Int*, 28: 871-880, 2017
23. Cauley JA, Lui LY, Ensrud KE, Zmuda JM, Stone KL, Hochberg MC, Cummings SR: Bone mineral density and the risk of incident nonspinal fractures in black and white women. *Jama*, 293: 2102-2108, 2005
24. Stehman-Breen C: Osteoporosis and chronic kidney disease. *Semin Nephrol*, 24: 78-81, 2004
25. Gao P, D'Amour P: Evolution of the parathyroid hormone (PTH) assay--importance of circulating PTH immunoheterogeneity and of its regulation. *Clin Lab*, 51: 21-29, 2005

26. Herberth J, Monier-Faugere MC, Mawad HW, Branscum AJ, Herberth Z, Wang G, Cantor T, Malluche HH: The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients. *Clin Nephrol*, 72: 5-14, 2009
27. QickFacts; Marshfield, Wisconsin. United States Census Bureau, July 2016
28. Waghray A, Milas M, Nyalakonda K, Siperstein AE: Falsely low parathyroid hormone secondary to biotin interference: a case series. *Endocr Pract*, 19: 451-455, 2013

Table 1: Subject Characteristics		
		All Subjects n=7594
Clinical	Age, years	68 ± 13
	Female Gender	4176 (55%)
	Tobacco use	4129 (54%)
	Duration of care at Marshfield Clinic	24 ± 15 years
Prevalence of Comorbidities	Coronary artery or peripheral vascular disease	4981 (66%)
	Diabetes	3875 (51%)
	Hypertension	6793 (89%)
	Hyperlipidemia	3606 (47%)
	Obesity	3141 (41%)
Labs	GFR, mL/minute	39 ± 16
	PTH, pg/mL	98 ± 91
Medication	Bisphosphonates	100 (1.3%)
	Denosumab or teriparatide	3 (0.04%)
	Estrogen, raloxifene, testosterone	62 (0.8%)
Outcomes	Fractures	1408 (19%)
	Vascular Events	4533 (60%)
	Death	2196 (29%)

Table 2: Multiple Co-Variate Models Predicting Hazard Ratios for Fracture, Vascular Events and Death in 7594 Subjects, with PTH measured using any assay

		Fracture		Vascular Events		Death	
Covariates		HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95%CI)	p-value
Clinical	Age ≤69 years	0.32 (0.27, 0.38)	<0.001	0.34 (0.31, 0.38)	<0.001	0.18 (0.16, 0.21)	<0.001
	Age 70-79	0.35 (0.30, 0.42)	<0.001	0.48 (0.43, 0.53)	<0.001	0.31 (0.27, 0.35)	<0.001
	Age 80-89	0.46 (0.40, 0.53)	<0.001	0.63 (0.58, 0.68)	<0.001	0.44 (0.40, 0.49)	<0.001
	Age ≥90 years	referent		referent		referent	
	Female Gender	1.65 (1.47, 1.85)	<0.001	0.77 (0.72, 0.81)	<0.001	0.73 (0.67, 0.80)	<0.001
	Tobacco Use	0.89 (0.81, 1.00)	0.058	1.04 (0.98, 1.11)	0.174	0.77 (0.71, 0.84)	<0.001
Comorbidities	Vascular disease	1.62 (1.42, 1.85)	<0.001	-	-	2.14 (1.88, 2.43)	<0.001
	Diabetes	1.03 (0.92, 1.15)	0.567	1.40 (1.32, 1.49)	<0.001	1.24 (1.14, 1.36)	<0.001
	Hypertension	0.98 (0.79, 1.20)	0.823	1.18 (1.04, 1.33)	0.010	0.65 (0.56, 0.75)	<0.001
	Hyperlipidemia	0.93 (0.83, 1.04)	0.198	1.10 (1.04, 1.17)	0.008	0.82 (0.75, 0.8964)	<0.001
	Obesity	0.87 (0.77, 0.98)	0.018	1.11 (1.04, 1.18)	0.002	0.85 (0.77, 0.93)	<0.001
Labs	GFR, mL/minute	1.01 (1.01, 1.01)	<0.001	0.99 (0.99, 1.00)	<0.001	0.97 (0.96, 0.9706)	<0.001
	PTH > cutpoint ^a	1.00 (1.00, 1.00)	0.0376	1.00 (1.00, 1.00)	<0.001	1.00 (1.00, 1.00)	<0.001
	PTH < cutpoint ^a	0.97 (0.96, 0.98)	<0.001	1.00 (0.99, 1.00)	0.621	0.98 (0.98, 0.99)	<0.001
Meds	Biophosphonates	1.27 (0.86, 1.87)	0.231	0.83 (0.63, 1.08)	0.169	0.82 (0.55, 1.23)	0.293
	Other ^b	0.89 (0.49, 1.61)	0.695	1.02 (0.74, 1.41)	0.901	0.84 (0.50, 1.43)	0.600

^aPTH cutpoint = 23 pg/mL for fractures, 50 pg/mL for vascular events, and 50 pg/mL for death

^bOther medications included estrogen, raloxifene and testosterone

Table 3: Multiple Co-Variate Models Predicting Hazard Ratios for Fracture, Vascular Events and Death in 5108 Patients with 2nd Generation PTH Values Above and Below Thresholds

		Fracture		Vascular Events		Death	
Covariates		HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Clinical	Age ≤59 years	0.47 (0.36, 0.63)	<0.001	0.44 (0.39, 0.49)	<0.001	0.30 (0.26, 0.34)	<0.001
	Age 60-69	0.54 (0.42, 0.69)	<0.001	0.56 (0.50, 0.62)	<0.001	0.40 (0.36, 0.45)	<0.001
	Age 70-79	0.75 (0.60, 0.92)	0.006	0.70 (0.63, 0.77)	<0.001	0.58 (0.52, 0.64)	<0.001
	Age ≥80 years	referent		referent		referent	
	Male Gender	0.69 (0.58, 0.84)	<0.001	1.28 (1.18, 1.38)	<0.001	1.26 (1.16, 1.38)	<0.001
	Tobacco Use	0.93 (0.79, 1.11)	0.427	1.07 (0.99, 1.16)	0.069	1.01 (0.93, 1.10)	0.752
Comorbidities	Vascular disease	1.80 (1.44, 2.26)	<0.001	-	-	1.61 (1.44, 1.79)	<0.001
	Diabetes	1.18 (1.00, 1.40)	0.055	1.29 (1.19, 1.39)	<0.001	1.23 (1.13, 1.33)	<0.001
	Hypertension	1.28 (0.84, 1.94)	0.249	1.05 (0.89, 1.23)	0.596	0.75 (0.64, 0.88)	<0.001
	Hyperlipidemia	0.99 (0.83, 1.17)	0.887	0.99 (0.93, 1.07)	0.879	0.80 (0.74, 0.86)	<0.001
	Obesity	0.89 (0.75, 1.07)	0.212	1.12 (1.04, 1.21)	0.003	0.91 (0.84, 0.99)	0.029
Labs	GFR, mL/minute	1.00 (0.99, 1.00)	0.268	0.99 (0.99, 0.99)	<0.001	0.98 (0.98, 0.98)	<0.001
	PTH < cutpoint ^a	0.95 (0.78, 1.15) ^b	0.605	1.11 (1.00, 1.23)	0.058	1.05 (0.89, 1.25)	0.546
	PTH > cutpoint ^a	1.16 (0.93, 1.45) ^b	0.195	1.18 (1.09, 1.27)	<0.001	1.19 (1.09, 1.30)	<0.001
Meds	Biophosphonates	1.65 (1.35, 2.01)	<0.001	1.00 (0.90, 1.11)	0.988	1.09 (0.98, 1.22)	0.126
	Other ^c	1.50 (1.22, 1.85)	<0.001	0.93 (0.83, 1.03)	0.176	0.89 (0.79, 1.01)	0.068

^aPTH cutpoint = 101 pg/mL for fractures, 69 pg/mL for vascular events and 58 pg/mL for death

^bIn the fracture model using PTH as a continuous variable, PTH remained a significant independent risk factor (p=0.042).

^cOther medications included estrogen, raloxifene and testosterone

Figure 1: Ten-Year Probability of Fractures, Vascular Events and Death based on Baseline Parathyroid Hormone Levels

Figure 1 legend: The figure demonstrates the U-shaped curve of the relationship between baseline parathyroid hormone (PTH) levels and ten-year probability of clinical fractures, vascular events and death. The PTH level at which fractures, vascular events and death was lowest equaled 23 pg/mL, 50 pg/mL and 50 pg/mL, respectively. PTH was measured using a 1st, 2nd or 3rd generation assay.

Figure 2: Ten-Year Probability of Fracture; Analysis Restricted to 2nd Generation Parathyroid Hormone Assay Results

Figure 2 legend: The figure demonstrates a linear relationship between baseline parathyroid hormone levels and ten-year probability of clinical fractures. While there was a small inflection point at a PTH value of 101 pg/mL, the hazards of fracture rose steadily with increasing PTH values.

Figure 3: Ten-Year Probability of Vascular Events and Death; Analysis Restricted to 2nd Generation Parathyroid Hormone Assay Results.

Figure 3 legend: The figure demonstrates that hazards of vascular events and death were lowest at PTH values of 69 and 59 ng/mL, respectively.

Figure 4: Ten-Year Probability of Fracture; Analysis Restricted to 2nd Generation Parathyroid Hormone Assay Results

Figure 4 legend: The figure demonstrates that the hazard of any event (fracture, vascular event or death) was lowest at a baseline PTH of 58 pg/mL.

Appendix Table 1: 2003 National Kidney Foundation Target Parathyroid Hormone (PTH) Levels				
CKD Stage, GFR	PTH	Phosphate	Calcium	Calcium x Phosphate
Stage 3, 30-59 mL/minute	35-70 pg/mL	1.7-4.6 mg/dL	<10.4 mg/dL	<55
Stage 4, 15-29 mL/minute	70-110 pg/mL			
All values are serum levels. Calcium levels are corrected for serum albumin.				

Appendix Table 2: Characteristics of 5108 Subjects in Sensitivity Analysis		
Clinical	Age, years	68 ± 17
	Male Gender	2433 (48%)
	Tobacco use	3031 (59%)
	Duration of care at Marshfield Clinic	23 ± 10 years
Prevalence of Comorbidities	Coronary artery or peripheral vascular disease	3644 (64%)
	Diabetes	2725 (53%)
	Hypertension	4730 (93%)
	Hyperlipidemia	2671 (52%)
	Obesity	2350 (46%)
Labs	GFR, mL/minute	35 ± 13
	PTH, pg/mL	19 ± 17
Medication	Bisphosphonates	709 (14%)
	Denosumab or teriparatide	113 (2%)
	Estrogen, raloxifene, testosterone	519 (10%)
Outcomes	Fractures	921 (18%)
	Vascular Events	3644 (71%)
	Death	2865 (56%)

Figure 1: 10-Year Probability of Fracture, Vascular Events & Death versus Baseline PTH Levels

Figure 2: 10-Year Probability of Fracture 2nd generation PTH assay

Figure 3: 10-Year Probability of Vascular Events & Death using 2nd generation PTH assay

Figure 4: 10-Year Probability of Composite Outcome 2nd generation PTH assay